Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

21 Jul 2023

Bright Minds Biosciences Announces Positive Data for Phase 1 Study of BMB-101

Bright Minds Biosciences announced the successful completion of its three-part Phase 1 study of BMB-101...

By Microdose NewsDesk

Breaking News

20 Jul 2023

Filament Health Heading to NASDAQ With SPAC Merger

The agreement would merge Filament with Jupiter Acquisition Corporation (NASDAQ: JAQC)...

By Microdose NewsDesk

Science

20 Jul 2023

New Study Shows Ketamine Effective Against Treatment-Resistant Depression

Results from a phase 3 trial show that generic ketamine was safe and effective in treating patients with treatment-resistant depression....

By Microdose NewsDesk
DMT

Industry

19 Jul 2023

PharmaTher Announces Positive Research Results for DMT and Investment into Sairiyo Therapeutics

PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Don’t Miss

17 Jul 2023

News You Might Have Missed: July 17th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Breaking News, Science

17 Jul 2023

Positive Data From COMPASS Pathways’ Phase 2 Trial Combining Psilocybin & SSRIs

Results of COMPASS Pathways’ study suggests that SSRIs do not interfere with the potential therapeutic effect of COMP360...

By Microdose NewsDesk

Science

14 Jul 2023

New Paper Discusses Value of Psychedelic-Assisted Psychotherapy

A new paper discusses the potential problems of using the term “psychedelic-assisted psychotherapy” for all psychedelic treatment modalities....

By Microdose NewsDesk
mushrooms decrim

Industry

14 Jul 2023

Legal Psychedelics: Which Compounds Will Be Approved Next?

Which psychedelics will be next to be FDA approved? We take a closer look....

By Microdose NewsDesk

Science

12 Jul 2023

New Study Shows Microdosing Psychedelics Makes You Feel More Authentic

A new study shows that microdosing can be associated with an increased sense of authenticity....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.